SAMD9
Basic information
Region (hg38): 7:93099513-93118023
Previous symbols: [ "C7orf5" ]
Links
Phenotypes
GenCC
Source:
- MIRAGE syndrome (Definitive), mode of inheritance: AD
- MIRAGE syndrome (Moderate), mode of inheritance: AD
- normophosphatemic familial tumoral calcinosis (Moderate), mode of inheritance: AR
- normophosphatemic familial tumoral calcinosis (Supportive), mode of inheritance: AR
- MIRAGE syndrome (Supportive), mode of inheritance: AD
- MIRAGE syndrome (Definitive), mode of inheritance: AD
- normophosphatemic familial tumoral calcinosis (Moderate), mode of inheritance: AR
- monosomy 7 myelodysplasia and leukemia syndrome 2 (Limited), mode of inheritance: AD
- monosomy 7 myelodysplasia and leukemia syndrome 2 (Limited), mode of inheritance: Unknown
- MIRAGE syndrome (Strong), mode of inheritance: AD
- normophosphatemic familial tumoral calcinosis (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Mirage syndrome; Monosomy 7 myelodysplasia and leukemia syndrome 2; Tumoral calcinosis, normophosphatemic, familial | AD/AR | Allergy/Immunology/Infectious; Endocrine; Hematologic; Musculoskeletal; Oncologic | Mirage syndrome can include anemia and thrombocytopenia requiring transfusions; Individuals can have severe and recurrent infections, and awareness may allow preventive measures and early and aggressive treatment of infections; Individuals may have salt-wasting adrenal hypoplasia, and awareness may allow prompt recognition and treatment to manage electrolyte and endocrine sequelae; For individuals with Tumoral calcinosis, surveillance/early treatment of tumoral calcinosis may reduce morbidity; Monosomy 7 myelodysplasia and leukemia syndrome 2 involves germline genetic anomaly as well as associated somatic loss of chromosome 7, and results in increased risk of hematologic malignancy such that awareness may allow early diagnosis and management of disease | Allergy/Immunology/Infectious; Dental; Dermatologic; Endocrine; Hematologic; Musculoskeletal; Neurologic; Oncologic; Ophthalmologic | 3366131; 15133511; 16960814; 18094730; 27182967; 28487541; 30046003; 30322869 |
ClinVar
This is a list of variants' phenotypes submitted to
- MIRAGE syndrome (6 variants)
- not provided (6 variants)
- SAMD9-related disorder (2 variants)
- Inborn genetic diseases (2 variants)
- Normophosphatemic familial tumoral calcinosis (1 variants)
- See cases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SAMD9 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 386 | 392 | ||||
missense | 13 | 521 | 23 | 10 | 574 | |
nonsense | 42 | 45 | ||||
start loss | 2 | |||||
frameshift | 43 | 49 | ||||
inframe indel | 10 | 10 | ||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 2 | |||||
Total | 9 | 20 | 620 | 411 | 14 |
Highest pathogenic variant AF is 0.00000658
Variants in SAMD9
This is a list of pathogenic ClinVar variants found in the SAMD9 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
7-93101320-T-C | not specified | Uncertain significance (Jun 08, 2019) | ||
7-93101327-C-T | SAMD9-related disorder | Likely benign (Jun 18, 2019) | ||
7-93101327-CTT-C | Likely benign (Aug 04, 2023) | |||
7-93101333-C-T | Uncertain significance (May 25, 2022) | |||
7-93101337-T-C | Likely benign (Apr 22, 2023) | |||
7-93101338-T-A | Uncertain significance (Jan 10, 2024) | |||
7-93101341-A-G | Uncertain significance (Jun 27, 2019) | |||
7-93101351-C-A | Uncertain significance (Oct 20, 2023) | |||
7-93101351-C-T | Uncertain significance (Feb 18, 2024) | |||
7-93101355-T-C | Likely benign (Oct 17, 2023) | |||
7-93101356-G-A | Uncertain significance (Feb 07, 2024) | |||
7-93101358-G-A | Likely benign (Mar 16, 2022) | |||
7-93101358-G-C | Likely benign (Feb 22, 2023) | |||
7-93101360-C-T | SAMD9-related disorder | Uncertain significance (Oct 29, 2023) | ||
7-93101364-A-G | Conflicting classifications of pathogenicity (Oct 03, 2023) | |||
7-93101365-A-G | not specified • MIRAGE syndrome;Monosomy 7 myelodysplasia and leukemia syndrome 2;Normophosphatemic familial tumoral calcinosis • SAMD9-related disorder | Benign/Likely benign (Apr 01, 2024) | ||
7-93101367-G-A | Likely benign (Mar 07, 2023) | |||
7-93101369-A-G | SAMD9-related disorder | Uncertain significance (Nov 04, 2022) | ||
7-93101373-T-C | Likely benign (Sep 04, 2023) | |||
7-93101374-C-A | Uncertain significance (Feb 04, 2022) | |||
7-93101374-C-T | not specified • SAMD9-related disorder | Conflicting classifications of pathogenicity (May 30, 2024) | ||
7-93101379-G-A | Likely benign (Aug 29, 2023) | |||
7-93101382-A-G | Likely benign (Jan 05, 2023) | |||
7-93101388-C-T | Likely benign (Dec 11, 2023) | |||
7-93101390-C-T | SAMD9-related disorder | Uncertain significance (Mar 20, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SAMD9 | protein_coding | protein_coding | ENST00000379958 | 1 | 18508 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.05e-33 | 0.0000242 | 124725 | 6 | 1008 | 125739 | 0.00404 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.769 | 709 | 769 | 0.922 | 0.0000384 | 10594 |
Missense in Polyphen | 173 | 186.49 | 0.92767 | 2651 | ||
Synonymous | 0.0796 | 277 | 279 | 0.994 | 0.0000141 | 2894 |
Loss of Function | 0.104 | 51 | 51.8 | 0.984 | 0.00000288 | 751 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0363 | 0.0362 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00256 | 0.00256 |
Finnish | 0.000464 | 0.000462 |
European (Non-Finnish) | 0.00178 | 0.00178 |
Middle Eastern | 0.00256 | 0.00256 |
South Asian | 0.00304 | 0.00304 |
Other | 0.00278 | 0.00277 |
dbNSFP
Source:
- Function
- FUNCTION: May play a role in the inflammatory response to tissue injury and the control of extra-osseous calcification, acting as a downstream target of TNF-alpha signaling. Involved in the regulation of EGR1, in coordination with RGL2. May be involved in endosome fusion. {ECO:0000269|PubMed:16960814, ECO:0000269|PubMed:18094730, ECO:0000269|PubMed:21160498, ECO:0000269|PubMed:24029230}.;
- Disease
- DISEASE: Tumoral calcinosis, normophosphatemic, familial (NFTC) [MIM:610455]: An uncommon, life-threatening disorder characterized by progressive deposition of calcified masses in cutaneous and subcutaneous tissues. Serum phosphate levels are normal. Clinical features include painful calcified ulcerative lesions and massive calcium deposition in the mid- and lower dermis, severe skin and bone infections, erythematous papular skin eruption in infancy, conjunctivitis, and gingivitis. NFTC shows a striking resemblance to acquired dystrophic calcinosis, in which tissue calcification occurs as a consequence of tissue injury/inflammation. {ECO:0000269|PubMed:16960814, ECO:0000269|PubMed:18094730}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: MIRAGE syndrome (MIRAGE) [MIM:617053]: A form of syndromic adrenal hypoplasia characterized by myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy. {ECO:0000269|PubMed:27182967}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.0928
Intolerance Scores
- loftool
- 0.991
- rvis_EVS
- 1.12
- rvis_percentile_EVS
- 92.11
Haploinsufficiency Scores
- pHI
- 0.115
- hipred
- N
- hipred_score
- 0.112
- ghis
- 0.437
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.258
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Gene ontology
- Biological process
- endosomal vesicle fusion
- Cellular component
- cytoplasm;cytosol;intracellular membrane-bounded organelle
- Molecular function
- protein binding